Siewert Type 1 GEJ Cancer clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Sorry, in progress, not accepting new patients
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
at UCLA
Our lead scientists for Siewert Type 1 GEJ Cancer research studies include Lee S. Rosen, MD.
Last updated: